Cell Therapeutics Starts NSCLC Phase III, Eyes One More In 2002 Oct. 8, 2002 By Brady Huggett No Comments
Cell Therapeutics Starts NSCLC Phase III, Eyes One More In 2002 Oct. 8, 2002 By Brady Huggett No Comments
Lilly Loans Isis $21M To Build Affinitac Manufacturing Space Oct. 2, 2002 By Brady Huggett No Comments
Lilly Loans Isis $21M To Build Affinitac Manufacturing Space Oct. 2, 2002 By Brady Huggett No Comments
IntraBiotics' Iseganan Fails To Reduce Mucositis In Phase III Oct. 1, 2002 By Brady Huggett No Comments IntraBiotics Pharmaceuticals Inc. stopped development of iseganan for mucositis following a Phase III failure. (BioWorld Today)Read More
IntraBiotics' Iseganan Fails To Reduce Mucositis In Phase III Oct. 1, 2002 By Brady Huggett No Comments IntraBiotics Pharmaceuticals Inc. stopped development of iseganan for mucositis following a Phase III failure. (BioWorld Today)Read More
Genome Therapeutics To Reduce Staff, Drop Early Research Efforts Sep. 26, 2002 By Brady Huggett No Comments
Genome Therapeutics To Reduce Staff, Drop Early Research Efforts Sep. 26, 2002 By Brady Huggett No Comments
